Bone Health Before Spine Surgery: Which Anabolic Drugs Actually Move the Needle?

The setup is the kind of real-world dataset biohackers tend to trust more than tightly controlled trials. Researchers at a single multisite institution pulled records on 267 preoperative spine surgery patients — median age 74, two-thirds female — who had been treated with one of four drugs: the anabolics teriparatide and romosozumab, or the antiresorptives denosumab and alendronate. They measured lumbar Hounsfield Units before and after treatment and asked a simple question: who crossed a clinically meaningful threshold of at least a 7-point HU improvement?

Just under half — 127 patients, or 47.6% — did. That headline number is worth sitting with. It says the modern pre-op bone toolkit moves measurable density in roughly one in two patients within a treatment window, which is genuinely useful, and also that the other half didn't clear the bar. For a Protocols-section reader, this is the moderate-evidence reality: real signal, real ceiling.

The comparison spans two mechanistic camps. Anabolics — teriparatide (a PTH analog) and romosozumab (a sclerostin-blocking monoclonal antibody) — push osteoblasts to build new bone. Antiresorptives — denosumab (a RANKL inhibitor) and alendronate (a bisphosphonate) — slow the osteoclasts that tear bone down. In the cohort, alendronate (95 patients) and denosumab (113) were the workhorses; romosozumab (31) and teriparatide (28) were the smaller, more targeted groups, typically reserved for higher-risk bone.

The univariable comparisons showed the groups weren't apples-to-apples to begin with: they differed significantly by age, sex, BMI, frailty scores, and even baseline HU. That's the texture of real clinical practice — the sicker, frailer, thinner-boned patients tend to get routed toward the anabolics. Any honest read of the data has to account for that selection.

The most actionable finding for the quantified-self crowd isn't which drug ranked first — it's that the patient's underlying frailty appears to shape who responds. The study explicitly set out to identify factors influencing treatment response, leaning on two indices most readers won't have heard of: the modified Frailty Index (mFI) and the Risk Analysis Index (RAI). Both differed significantly across medication groups in the baseline comparisons, and both were built into the logistic regression models predicting HU gain.

The implication, framed cautiously: bone-building drugs don't operate in a vacuum. Pre-treatment HU, BMI, and composite frailty scores all carry information about who will and won't cross the 7-point threshold. For a reader optimizing before elective spine surgery, that suggests the protocol question isn't only "which drug?" but "what shape am I in when I start it?" Sarcopenia, nutritional status, and overall physiologic reserve are not side quests here — they're part of the response curve.

One reason this paper resonates with the data-obsessed: Hounsfield Units are already sitting on most pre-op CT scans, no extra DEXA appointment required. HU is a density measurement baked into CT physics; in the lumbar spine, it correlates with bone mineral density and has become a pragmatic surrogate for fracture and instrumentation risk. The investigators chose a ≥7-point improvement as their threshold for "responder," which gives readers a concrete, repeatable yardstick — the kind of pre/post number you can actually track between scans rather than a vague "bone got better."

Caveats apply. This is a single-institution retrospective cohort, not a randomized comparison. The drug groups weren't balanced. The follow-up windows and treatment durations weren't standardized in the abstract-level data. And HU change, while clinically meaningful, is a proxy for what surgeons actually care about: fewer mechanical failures after fusion. The paper is a useful map of the terrain, not a verdict.

For the n-of-1 mindset, the most honest takeaway is that pre-surgical bone optimization is now measurable, comparable, and worth asking about — but it's also a domain where the patient's underlying biology, captured imperfectly by frailty indices, sets a ceiling on what any drug can do in a short pre-op window. Modern anabolics are powerful tools. They are not, on the evidence to hand, magic ones. Bring the CT number to the conversation, and let a clinician who knows the rest of the chart pick the protocol.